{"id":"NCT00654095","sponsor":"Organon and Co","briefTitle":"Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia (P05456)","officialTitle":"Open-label, Long-term Study of Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia Who Have Not Reached LDL-cholesterol Target With HMG-CoA Reductase Inhibitors","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-12-01","primaryCompletion":"2009-06-01","completion":"2009-06-01","firstPosted":"2008-04-07","resultsPosted":"2010-10-05","lastUpdate":"2024-05-21"},"enrollment":146,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hypercholesterolemia"],"interventions":[{"type":"DRUG","name":"Ezetimibe","otherNames":["SCH 58235"]},{"type":"DRUG","name":"atorvastatin","otherNames":[]}],"arms":[{"label":"Ezetimibe + Atorvastatin","type":"EXPERIMENTAL"}],"summary":"Evaluate the safety of the long-term (1 year) coadministration of ezetimibe and atorvastatin in participants with hypercholesterolemia who have not reached low density lipoprotein (LDL)-cholesterol target with 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors.","primaryOutcome":{"measure":"Number of Participants With Adverse Events and Adverse Reactions","timeFrame":"Throughout 1 year of study","effectByArm":[{"arm":"Ezetimibe + Atorvastatin","deltaMin":141,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":146},"commonTop":["NASOPHARYNGITIS","ALANINE AMINOTRANSFERASE INCREASED","C-REACTIVE PROTEIN INCREASED","GAMMA-GLUTAMYLTRANSFERASE INCREASED","BLOOD CREATINE PHOSPHOKINASE INCREASED"]}}